Trial Profile
Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Oct 2022
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Prader-Willi syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Novo Nordisk
- 01 Oct 2022 Primary endpoint (Change in body mass index (BMI) standard deviation score (SDS)) has not been met, according to results published in the Journal of Clinical Endocrinology and Metabolism
- 01 Oct 2022 Results published in the Journal of Clinical Endocrinology and Metabolism
- 02 Dec 2020 Status changed from active, no longer recruiting to completed.